DiaGyn

Company Overview

Snapshot

Founded in September 2015 by Roy Farfara, DiaGyn operated with 1–10 employees, focusing on developing solutions for women's health. The company ceased operations in December 2022.

Business overview

DiaGyn specializes in developing targeted chemotherapy solutions for breast and ovarian cancer, integrating drug development and molecular genomics with personalized therapeutic approaches. The company's core product, DIG790, utilizes 100 nm mesoporous silica nanoparticles loaded with docetaxel, designed to selectively release the drug into malignant cells while minimizing impact on normal tissues. DiaGyn primarily serves the healthcare and life sciences sector, with a focus on oncology and women's health.

Company Intelligence Q&A

What is DiaGyn's primary focus?

DiaGyn focuses on developing solutions for unmet needs in women's health, specifically targeting BRCA1/2 mutations in ovarian and breast cancer using nanoparticle technology for treatment.

What is DIG790?

DIG790 is DiaGyn's innovative product for advanced epithelial ovarian cancer (EOC), comprising 100 nm mesoporous silica nanoparticles loaded with docetaxel and capped with cyclodextrin for targeted drug release.

How does DiaGyn's nanoparticle technology work?

DiaGyn's nanoparticles feature a sensitive linker that selectively senses high levels of β-galactosidase and low pH in EOC cells, releasing the chemotherapy drug into malignant cells while largely sparing normal tissues.

When was DiaGyn founded?

DiaGyn was founded in September 2015.

What is the current operational status of DiaGyn?

DiaGyn ceased to operate in December 2022.